OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:34 UTC. Every row links to its source record.

PRAME PRAME nuclear receptor transcriptional regulator

ENSG00000185686 · protein coding · Open Targets profile

Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed:21822215, PubMed:26138980). The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed:26138980). In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromstin regulation (PubMed:21822215). Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis (PubMed:16179254). {ECO:0000269|PubMed:16179254, ECO:0000269|PubMed:21822215, ECO:0000269|PubMed:26138980}.

PRAME: inherited and tumour-mutation evidence across 15 cancers

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751melanomamelanomaacute myeloid leukemiaacute myeloid leukemialung carcinomalung carcinomauveal melanomauveal melanomalung cancerlung cancerhepatocellular carcinomahepatocellular carcinomacervical carcinomacervical carcinomacervical cancercervical cancertriple-negative breast carcinomatriple-negative breast carcinomaseminomaseminomanon-small cell lung carcinomanon-small cell lung carcinomadiffuse large B-cell lymphomadiffuse large B-cell lymphomalaryngeal squamous cell carcinomalaryngeal squamous cell carcinomacentral nervous system cancercentral nervous system cancergliomaglioma

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Antibody
UniProt loc high conf, GO CC high conf
PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 0.6549699902534485 (upper bound 0.9431700110435486). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of PRAME's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of PRAME's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.